Journals / Experimed / 2019 / Cilt: 9 - Sayı: 3

The Effects of Rifampicin on Neuronal Survival

Rifampisinin Nöronal Sağkalım Üzerine Etkileri

Journal
Experimed
Pages
138–142
Publication Date
2019-12-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Experimed 2019; 9(3): 138-42.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neurodegenerative diseases are characterized by the formation of insoluble aggregates of misfolded proteins in the central nervous system.
📊
Key Findings & Data:Rifampicin is an antibiotic commonly used in humans and known to easily penetrate into the brain after oral intake.
💡
Conclusion & Impact:Experimed 2019; 9(3): 138-42.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:Parkinson hastalığı · rifampisin · α-Sinüklein

Abstract

Neurodegenerative diseases are characterized by the formation of insoluble aggregates of misfolded proteins in the central nervous system. The β-amyloid protein in Alzheimer's disease and α-synuclein formation in Parkinson's disease (PD) may be given as examples. In addition to α-synuclein accumulation in Parkinson's disease, mechanisms such as oxidative stress, dysfunction of mitochondria, inflammation response, and apoptosis are known to be involved in the disease process. Since the mechanisms underlying these diseases are partially known, the drugs developed are intended to slow the disease process rather than cure them. Rifampicin is an antibiotic commonly used in humans and known to easily penetrate into the brain after oral intake. Studies have shown that rifampicin suppresses mitochondrial oxidative stress, eliminates α-synuclein fibrils and inhibits inflammation in in vitro and in vivo disease models. In this study, we reviewed recent studies on the neuronal protection of rifampicin and the effects of rifampicin on the pathophysiological mechanisms of PD. Cite this article as: Yurtsever İ, Emekli Alturfan E. The Effects of Rifampicin on Neuronal Survival. Experimed 2019; 9(3): 138-42.

Özet

Nörodejeneratif hastalıklar, merkezi sinir siteminde yanlış katlanmış proteinlerin çözünmeyen agregatlarının oluşumu ile karakterizedir. Bunlara örnek olarak; Alzheimer hastalığında β-amyloid protein ve Parkinson hastalığında α-sinüklein oluşumu verilebilir. Parkinson hastalığında α-sinüklein agregasyonuna ek olarak, oksidatif stress, mitokondri fonksiyon bozukluğu, inflamatuvar cevap, apoptoz gibi mekanizmaların hastalık sürecine katıldığı bilinmektedir. Bu hastalıkların altında yatan mekanizmalar tam olarak bilinmediği için, hastalığa ilişkin geliştirilen ilaçlar, hastalığı iyileştirmekten çok, hastalığın seyrini yavaşlatma eğilimindedir. Rifampisin insanlar tarafından sıkça kullanılan bir antibiyotiktir ve ağız yoluyla alındıktan sonra beyne kolaylıkla penetre olmaktadır. Rifampisinin in vivo ve in vitro hastalık modellerinde mitokondriyal oksidatif stresi baskıladığı, α-sinüklein fibrillerini ayrıştırdığı, inflamasyonu inhibe ettiğini gösteren çok sayıda çalışma mevcuttur. Biz bu çalışmada, rifampisinin nöronal korunumu üzerine raporlanan çalışmaları ve Parkinson hastalığı’nın patofizyolojik mekanizmaları üzerine rifampisinin etkilerini derledik. Cite this article as: Yurtsever İ, Emekli Alturfan E. The Effects of Rifampicin on Neuronal Survival. Experimed 2019; 9(3): 138-42.

🔖

Cite This Article

YURTSEVER, İ., ALTURFAN, E. E. (2019). The Effects of Rifampicin on Neuronal Survival. Experimed, Cilt: 9 - Sayı: 3, 138–142. https://ajindex.com/articles/50835

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ambrosi G, Cerri S, Blandini F. A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease. J Neural Transm 2014
  2. [CrossRef] 2. Giráldez-Pérez R, Antolín-Vallespín M, Muñoz M, Sánchez-Capelo A. Models of α-synuclein aggregation in Parkinson’s disease. Acta Neuropathol Commun 2014
  3. doi: 10.1186/s40478-014-0176-9. [CrossRef] 3. Blesa J, Trigo-Damas I, Quiroga-Varela A and Jackson-Lewis V R. Oxidative stress and Parkinson’s disease. Front Neuroanat 2015
  4. https://doi.org/10.3389/fnana.2015.00091 [CrossRef] 4. Franco-Iborra S, Vila M, Perier C. The Parkinson disease mitochondrial hypothesis: where are we at? Neuroscientist 2016
  5. [CrossRef] 5. Vivekanantham S, Shah S, Dewji R, Dewji A, Khatri C, Ologunde R. Neuroinflammation in Parkinson’s disease: role in neurodegeneration and tissue repair. Int J Neurosci 2015
  6. [CrossRef] 6. Guerra de Souza AC, Prediger RD, Cimarosti H. SUMO-regulated mitochondrial function in Parkinson’s disease. J Neurochem 2016
  7. [CrossRef] 7. Bi W, Zhu L, Jing X, Zeng Z, Liang Y, Xu A, et al. Rifampicin improves neuronal apoptosis in LPS-stimulated co-cultured BV2 cells through inhibition of the TLR-4 pathway. Mol Med Rep 2014
  8. [CrossRef] 8. Jing X, Shi Q, Bi W, Zeng Z, Liang Y, Wu X, et al. Rifampicin protects PC12 cells from rotenone-induced cytotoxicity by activating GRP78 via PERK-eIF2alpha-ATF4 pathway. PLoS One 2014
  9. doi: 10.1371/journal.pone.0092110.[CrossRef] 9. Xu J, Wei C, Xu C, Bennett M C, Zhang G, Li F, et al. Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an alpha-synuclein multimer. Brain Res 2007
  10. [CrossRef] 10. Bi W, Zhu L, Wang C, Liang Y, Liu J, Shi Q, et al. Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation. Brain Res 2011
  11. [CrossRef] 11. Greenamyre JT, Betarbet R, Sherer TB. The rotenone model of Parkinson’s disease: genes, environment, and mitochondria. Parkinsonism Relat Disord 2003
  12. 9 (Suppl 2): S59-S64. [CrossRef] 12. Testa CM, Sherer TB, Greenamyre JT. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res 2005
  13. [CrossRef] 13. Watanabe Y, Himeda T, Araki T. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson’s disease. Med Sci Monit 2005
  14. Sherer TB, Betarbet R, Stout